Literature DB >> 16145369

T2 clear cell renal cell carcinoma is a rare entity: a study of 120 clear cell renal cell carcinomas.

Stephen M Bonsib1.   

Abstract

PURPOSE: In 2002 the American Joint Committee on Cancer revised the TNM staging system, introducing subclassification for T1 tumors, and invasion of renal sinus fat and sinus veins in categories T3a and T3b, respectively. Since renal sinus invasion represents the most common site of extrarenal extension, the relationship between size, and renal sinus invasion and its effect on the T classification was examined in prospective fashion.
MATERIALS AND METHODS: A total of 175 renal cell carcinomas were examined in prospective fashion with careful evaluation for renal sinus invasion. A minimum of 5 blocks of the renal sinus-tumor interface were examined. Tumors were staged using the 2002 TNM formulation.
RESULTS: The distribution of tumors types was clear cell renal cell carcinoma (CC) in 120 cases, papillary renal cell carcinoma in 30, chromophobe renal cell carcinoma in 12 and miscellaneous other carcinomas in 13. T classifications correlated with tumor type. Only 3 of 30 papillary renal cell carcinomas (10%) and 2 of 9 chromophobe renal cell carcinomas (16.6%) demonstrated extrarenal extension compared with 59 of 120 CCs (49%) (p <0.01). Renal sinus invasion occurred more often than capsule invasion (49% vs 20%, p <0.01). No tumor invaded the capsule that did not also invade the sinus. Compared with 1.1 to 4 cm CCs, of which 85% were renal limited, only 32% of CCs that were 4.1 to 7 cm (p <0.01) and 3% of those larger than 7 cm were renal limited, that is T1b and T2, respectively.
CONCLUSIONS: The incidence of renal sinus invasion increases sharply after tumors exceed 4 cm. T1b CC is uncommon and T2 CC is rare if careful evaluation for sinus invasion is performed.

Entities:  

Mesh:

Year:  2005        PMID: 16145369     DOI: 10.1097/01.ju.0000173631.01329.1f

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  16 in total

1.  Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus.

Authors:  Ricardo A Rendon; Anil Kapoor; Rodney Breau; Michael Leveridge; Andrew Feifer; Peter C Black; Alan So
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

Review 2.  [Renal cancer biomarkers. What is justified?].

Authors:  H Moch
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

Review 3.  Early renal cell cancer.

Authors:  Yoshihiko Tomita
Journal:  Int J Clin Oncol       Date:  2006-02       Impact factor: 3.402

4.  Validation of the 2009 TNM Classification for Renal Cell Carcinoma: Comparison with the 2002 TNM Classification by Concordance Index.

Authors:  Chunwoo Lee; Dalsan You; Junsoo Park; In Gab Jeong; Cheryn Song; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim
Journal:  Korean J Urol       Date:  2011-08-22

Review 5.  Biomarkers in renal cancer.

Authors:  Holger Moch; John Srigley; Brett Delahunt; Rodolfo Montironi; Lars Egevad; Puay Hoon Tan
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

6.  Pathological Stage T3a Significantly Increases Disease Recurrence across All Tumor Sizes in Renal Cell Carcinoma.

Authors:  Michael Chevinsky; Mariam Imnadze; Alexander Sankin; Andrew Winer; Roy Mano; Christopher Jakubowski; Joseph Mashni; Daniel D Sjoberg; Ying-Bei Chen; Satish K Tickoo; Victor E Reuter; A Ari Hakimi; Paul Russo
Journal:  J Urol       Date:  2015-02-09       Impact factor: 7.450

Review 7.  The changing face of renal cell carcinoma pathology.

Authors:  Hakan Aydin; Ming Zhou
Journal:  Curr Oncol Rep       Date:  2008-05       Impact factor: 5.075

8.  [WHO classification 2016 and first S3 guidelines on renal cell cancer: What is important for the practice?].

Authors:  H Moch
Journal:  Pathologe       Date:  2016-03       Impact factor: 1.011

9.  New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.

Authors:  Kiril Trpkov; Ondrej Hes; Sean R Williamson; Anthony J Gill; Adebowale J Adeniran; Abbas Agaimy; Reza Alaghehbandan; Mahul B Amin; Pedram Argani; Ying-Bei Chen; Liang Cheng; Jonathan I Epstein; John C Cheville; Eva Comperat; Isabela Werneck da Cunha; Jennifer B Gordetsky; Sounak Gupta; Huiying He; Michelle S Hirsch; Peter A Humphrey; Payal Kapur; Fumiyoshi Kojima; Jose I Lopez; Fiona Maclean; Cristina Magi-Galluzzi; Jesse K McKenney; Rohit Mehra; Santosh Menon; George J Netto; Christopher G Przybycin; Priya Rao; Qiu Rao; Victor E Reuter; Rola M Saleeb; Rajal B Shah; Steven C Smith; Satish Tickoo; Maria S Tretiakova; Lawrence True; Virginie Verkarre; Sara E Wobker; Ming Zhou
Journal:  Mod Pathol       Date:  2021-03-04       Impact factor: 8.209

10.  Correcting the Shrinkage Effects of Formalin Fixation and Tissue Processing for Renal Tumors: toward Standardization of Pathological Reporting of Tumor Size.

Authors:  Thu Tran; Chandru P Sundaram; Clinton D Bahler; John N Eble; David J Grignon; M Francesca Monn; Novae B Simper; Liang Cheng
Journal:  J Cancer       Date:  2015-07-02       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.